Dedifferentiated and Undifferentiated Melanoma: The Chameleon of Surgical Pathology [0.03%]
去分化的黑色素瘤及未分化的黑色素瘤：外科病理中的变色龙
Ann-Kristin Iro,Abbas Agaimy
Ann-Kristin Iro
Melanoma showing subclonal (dedifferentiated) or global (undifferentiated) loss of all routinely used immunophenotypic melanocytic markers has been the topic of several studies in recent years. These recent studies highlighted a significant...
Nicolas Macagno,Mélanie Legrand,Thibault Kervarrec
Nicolas Macagno
This article examines cutaneous neoplasms with NUTM1 gene fusions, focusing on poroma, porocarcinoma, and primary cutaneous NUT carcinoma. Diagnostic challenges include differentiating primary cutaneous NUT carcinoma from extracutaneous NUT...
Hannah Y Wen
Hannah Y Wen
Matthew G Hanna
Matthew G Hanna
The integration of digital and computational pathology into breast pathology practice is evolving the field. Leveraging machine learning, pathologists can augment their workflows in disease classification, biomarker quantification, and outc...
Theodore Vougiouklakis,Dara S Ross
Theodore Vougiouklakis
Biomarker testing, multigene expression assays, and mutation profiling can be employed to direct treatment following the pathologic diagnosis of an invasive breast carcinoma. This article provides a summary for the surgical pathologist, und...
Melinda E Sanders
Melinda E Sanders
Immunohistochemistry is utilized in all facets of diagnostic breast pathology. Recognition of aberrant E-cadherin expression in invasive lobular carcinoma and lobular carcinoma avoids misinterpretation. A context-focused battery of stains w...
Prognostic and Predictive Assays in Invasive Breast Carcinoma Beyond Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 [0.03%]
三阴性乳腺癌以外的侵袭性乳腺癌的预后和预测检测超越雌激素受体、孕激素受体和人表皮生长因子受体2
Lauren Ashley Duckworth,Raza Syed Hoda
Lauren Ashley Duckworth
This review examines prognostic and predictive molecular assays in invasive breast carcinoma beyond estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. It highlights the clinical utility of multigene assa...
Hormone Receptor and HER2 Testing in Breast Cancer: Latest Questions Answered [0.03%]
乳腺癌中的激素受体和HER2检测：最新问题解答
Joanna Solarewicz,Kimberly H Allison
Joanna Solarewicz
Evolving data continue to require pathologists to adjust breast cancer biomarker interpretation and reporting. ER low positive and HER2 low/ultralow are not distinct subtypes of breast cancer but have important treatment implications. ER lo...
Tumor Infiltrating Lymphocytes in Breast Cancer: Why Is It Useful to Know? [0.03%]
肿瘤浸润淋巴细胞在乳腺癌中的作用：为什么要知道？
Sai K Maley,Reena Khiroya,Elena Provenzano et al.
Sai K Maley et al.
Stromal tumor infiltrating lymphocytes (sTILs) in breast cancer is an easily evaluable histopathological biomarker that is shown to be robust and reproducible with prognostic and predictive value in triple negative breast cancer (TNBC), HER...
High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations [0.03%]
核心针吸活检的高风险乳腺病变：升级率和管理建议
Anne Grabenstetter
Anne Grabenstetter
High-risk lesions of the breast confer an increased risk for breast cancer. Due to wide variations in the reported rate of upgrade to carcinoma at excision, optimal management of these lesions is controversial. Intraductal papillomas, mucoc...